RE:Recruiting Looks like Dr, Grinspoon has gotten tired of waiting and went back to the NIH to fund this trial and keep things on Egrifta moving along. Since NAFLD is not yet something the FDA will approve a drug for, I suppose he is hoping whatever this trial discovers will change that attitude. Or, he may not really care that much about drug approval and is simply trying to push the science forward in the absence of TH being able to start the trial. Maybe he would have pursued this trial even if the NASH pahse III had already started. If nothing else, the free Egrifta he will recieve for this trial (I am assuming it will be given free or for a very low cost) should help keep Dr. Grinspoon in a good frame of mind on TH as he must be disappointed with them to some extent that NASH is on hold for now and cancer seems like TH's main gig.
scarlet1967 wrote: “What we are studying
We are doing this research study to find out if a drug called Tesamorelin can help people with nonalcoholic fatty liver disease (NAFLD). We have found that, on average, people with obesity have lower levels of growth hormone. Low levels of growth hormone may be related to developing NAFLD. Growth hormone is a hormone that helps children grow, and, in children and adults, regulates how the body uses and stores fat. Tesamorelin, the drug we are studying, increases the body’s growth hormone secretion. We would like to see if tesamorelin can reduce liver fat and improve liver health in adults who have NAFLD.”
https://rally.massgeneralbrigham.org/study/ghrh4nafld